Nanostructures for bypassing blood brain barrier

Current Bioactive Compounds

Volumn 5, Issue 3, 2009, Pages 195-205

  Wang, Junping ^a   Valmikinathan, Chandra M ^a   Yu, Xiaojun ^a  

^a Stevens Institute of Technology   (United States)

Author keywords

Blood brain barrier; Drug delivery; Imaging; Nanomaterials; Nanoparticles

Indexed keywords

CELL PENETRATING PEPTIDE; CYCLOSPORIN A; DENDRIMER; DOCETAXEL; DOXORUBICIN; ELACRIDAR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLYCOPROTEIN P; HALOPERIDOL; INSULIN; LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROGOL; METHOTREXATE; MONOCLONAL ANTIBODY 5A10; MONOCLONAL ANTIBODY OX26; NANOCARRIER; NANOCORE; NANOGEL; NANOMATERIAL; NANOPARTICLE; NANOSHELL; POLYMER; POLYMERIC MICELLE; SOLID LIPID NANOPARTICLE; TRANSACTIVATOR PROTEIN; TRANSFERRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; ZIDOVUDINE;

ADSORPTIVE MEDIATED TRANSCYTOSIS; BLOOD BRAIN BARRIER; BRAIN; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IMAGING SYSTEM; LIPID SOLUBILITY; MOLECULAR BIOLOGY; NANOTECHNOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTUM THEORY; RECEPTOR MEDIATED TRANSCYTOSIS; REVIEW; SIGNAL TRANSDUCTION; TRANSCYTOSIS;

EID: 70449864545     PISSN: 15734072     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340709789054777     Document Type: Review

References (158)

1. Roney, C., Kulkarni, P., Arora, V., Antich, P., Bonte, F., Wu, A., Mallikarjuana, N.N., Manohar, S., Liang, H.F., Kulkarni, A.R., Sung, H.W., Sairam, M., Aminabhavi, T.M. (2005) Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J. Control Release, 108(2-3), 193-214. (Pubitemid 41608654)
2. Lockman, P.R., Mumper, R.J., Khan, M.A., Allen, D.D. (2002) Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev. Ind. Pharm., 28(1), 1-13. (Pubitemid 34279373)
3. Chen, Y., Dalwadi, G., Benson, H.A. (2004) Drug delivery across the blood-brain barrier. Curr. Drug Deliv., 1(4), 361-376.
4. Sawyer, A.J., Piepmeier, J.M., Saltzman, W.M. (2006) New methods for direct delivery of chemotherapy for treating brain tumors. Yale J. Biol. Med., 79(3-4), 141-152.
5. Ferguson, S.D., Foster, K., Yamini, B. (2007) Convection-enhanced delivery for treatment of brain tumors. Exp. Rev. Anticancer Ther., 7(12 Suppl), S79-85.
6. Fournier, E., Passirani, C., Montero-Menei, C.N., Benoit, J.P. (2003) Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials, 24(19), 3311-3331. (Pubitemid 36577679)
7. Rautioa, J., Chikhale, P.J. (2004) Drug delivery systems for brain tumor therapy. Curr. Pharm. Des., 10, 1341-1353. (Pubitemid 38559751)
8. Olivier, J.C. (2005) Drug transport to brain with targeted nanoparticles. NeuroRx, 2(1), 108-119. (Pubitemid 40128031)
9. Kreuter, J. (2001) Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev., 47(1), 65-81. (Pubitemid 32209233)
10. Tiwari, S.B., Amiji, M.S. (2006) A review of nanocarrier-based CNS delivery systems. Curr. Drug Deliv., 3, 219-232.
11. Persidsky, Y., Ramirez, S.H., Haorah, J., Kanmogne, G.D. (2006) Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J. Neuroimmune Pharmacol., 1, 223-236. (Pubitemid 44244128)
12. Begley, D.J. (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther., 104(1), 29-45. (Pubitemid 39410561)
13. Ballabh, P., Braun, A., Nedergaard, M. (2004) The blood-brain barrier: an overview structure, regulation, and clinical implications. Neurobiol. Dis., 16, 1-13. (Pubitemid 38569790)
14. Eugenina, E.A., Berman, J. W. (2003) Chemokine-dependent mechanisms of leukocyte trafficking across a model of the blood-brain barrier. Methods, 29(4), 351-361. (Pubitemid 36513434)
15. Burke, M., Langer, R., Brim, H. (1999) Central nervous system: drug delivery to treat, John Wiley & Sons, Inc.: New York, NY.
16. Tusji, A. (2000) The blood-brain barrier and drug delivery to the CNS. Marcel Dekker, Inc.: New York, NY.
17. Wolburg, H., Lippoldt, A. (2002) Tight junctions of the blood-brain barrier: development, composition and regulation. Vasc. Pharmacol., 38(6), 323-337. (Pubitemid 36398254)
18. Mitic, L., Itallie, C.V., Anderson, J. (2000) Molecular physiology and pathophysiology of tight junctions. Am. J. Physiol. Gasterointest. Liver Physiol., 279, G250-G254.
19. Ueno, M. (2007) Molecular anatomy of the brain endothelial barrier: an overview of the distributional features. Curr. Med. Chem., 14(11), 1199-1206.
20. Abbott, N.J., Khan, E.U., Rollinson, C.M., Reichel, A., Janigro, D., Dombrowski, S.M., Dobbie, M.S., Begley, D.J. (2002) Drug resistance in epilepsy: the role of the blood-brain barrier. Novartis Found. Symp., 243, 38-47; discussion 47-53, 180-185
21. Neuwelt, E.A. (2004) Mechanisms of disease: the blood-brain barrier. Neurosurgery, 54(1), 131-140; discussion 141-142.
22. Pardridge, W.M. In Brain drug targeting, the future of brain drug development. Pardridge, W.M. Ed.; Cambridge University Press: Cambridge, 2001, pp. 36-81.
23. Schnyder, A., Huwyler, J. (2005) Drug transport to brain with targeted liposomes. NeuroRx, 2(1), 99-107. (Pubitemid 40128030)
24. Tsuji, A., Tamai, I.I. (1999) Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev., 36(2-3), 277-290. (Pubitemid 29121976)
25. Pardridge, W.M., Kang, Y.S., Buciak, J.L., Yang, J. (1995) Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res., 12(6), 807-816.
26. Li, H., Qian, Z.M. (2002) Transferrin/transferrin receptor-mediated drug delivery. Med. Res. Rev., 22(3), 225-250.
27. Drin, G., Rousselle, C., Scherrmann, J.M., Rees, A.R., Temsamani, J. (2002) Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors. AAPS PharmSci., 4(4), E26.
28. Girardin, F. (2006) Membrane transporter proteins: a challenge for CNS drug development. Dialogues Clin. Neurosci., 8(3), 311-321.
29. Jain, K.K. (2007) Nanobiotechnology-based drug delivery to the central nervous system. Neurodegener. Dis., 4(4), 287-291. (Pubitemid 47026182)
30. Kabanov, A.V., Batrakova, E.V. (2004) New technologies for drug delivery across the blood brain barrier. Curr. Pharm. Des., 10(12), 1355-1363. (Pubitemid 38578372)
31. Smith, M.W., Gumbleton, M. (2006) Endocytosis at the blood-brain barrier: from basic understanding to drug delivery strategies. J. Drug Target, 14(4), 191-214.
32. de Boer, A.G., Gaillard, P.J. (2007) Strategies to improve drug delivery across the blood-brain barrier. Clin. Pharmacokinet., 46(7), 553-576. (Pubitemid 47025357)
33. Bickel, U., Yoshikawa, T., Pardridge, W.M. (2001) Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev., 46(1-3), 247-279.
34. Jones, A.R., Shusta, E.V. (2007) Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm. Res., 24(9), 1759-1771. (Pubitemid 47206625)
35. Pardridge, W.M. (2007) Drug targeting to the brain. Pharm. Res., 24(9), 1733-1744.
36. Pardridge, W.M. (1984) Peptide drug delivery to the brain. Raven Physiol., 247, R768-R779.
37. Newton, H.B. (2006) Advances in strategies to improve drug delivery to brain tumors. Exp. Rev. Neurother., 6(10), 1495-1509. (Pubitemid 44690919)
38. Verbaeys, I., León-Tamariz, F., Buyse, J., De Cuyper, M., Pottel, H., Van Boven, M., Cokelaere, M. (2007) PEGylated cholecystokinin prolongs satiation in rats: dose dependency and receptor involvement. Br. J. Pharmacol., 152(3), 396-403. (Pubitemid 47511254)
39. Fleming, A.B., Haverstick, K., Saltzman, W.M. (2004) In vitro cytotoxicity and in vivo distribution after direct delivery of PEG-camptothecin conjugates to the rat brain. Bioconjug. Chem., 15(6), 1364-1375. (Pubitemid 39552027)
40. Tang, G.P., Zeng, J.M., Gao, S.J., Ma, Y.X., Shi, L., Li, Y., Too, H.P., Wang, S. (2003) Polyethylene glycol modified polyethylenimine for improved CNS gene transfer: effects of PEGylation extent. Biomaterials, 24(13), 2351-2362. (Pubitemid 36434055)
41. Pulkkinen, M., Pikkarainen, J., Wirth, T., Tarvainen, T., Haapa-Aho, V., Korhonen, H., Seppälä, J., Järvinen, K. (2008) Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity. Eur. J. Pharm. Biopharm., 70(1), 66-74.
42. Jeong Lee, H., Pardridge, W.M. (2000) Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease). J. Drug Target, 8(6), 413-424.
43. Kang, Y.S., Voigt, K., Bickel, U. (2000) Stability of the disulfide bond in an avidin-biotin linked chimeric peptide during in vivo transcytosis through brain endothelial cells. J. Drug Target, 8(6), 425-434. (Pubitemid 32366710)
44. Mishra, V., Mahor, S., Rawat, A., Gupta, P.N., Dubey, P., Khatri, K., Vyas, S.P. (2006) Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J. Drug Target, 14(1), 45-53.
45. Doi, A., Kawabata, S., Iida, K., Yokoyama, K., Kajimoto, Y., Kuroiwa, T., Shirakawa, T., Kirihata, M., Kasaoka, S., Maruyama, K., Kumada, H., Sakurai, Y., Masunaga, S., Ono, K., Miyatake, S. (2008) Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. J. Neurooncol., 87(3), 287-294.
46. Qian, Z.M., Li, H.Y., Sun, H.Z., Ho, K. (2002) Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev., 54, 561-587.
47. Lee, H.J., Engelhardt, B., Lesley, J., Bickel, U., Pardridge, W.M. (2000) Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J. Pharmacol. Exp. Ther., 292, 1048-1052. (Pubitemid 30136600)
48. Aktaş, Y., Yemisci, M., Andrieux, K., Gürsoy, R.N., Alonso, M.J., Fernandez-Megia, E., Novoa-Carballal, R., Quiñoá, E., Riguera, R., Sargon, M.F., Celik, H.H., Demir, A.S., Hincal, A.A.; Dalkara, T., Capan, Y., Couvreur, P. (2005) Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug. Chem., 16(6), 1503-1511. (Pubitemid 41681517)
49. Béduneau, A., Hindré, F., Clavreul, A., Leroux, J.C., Saulnier, P., Benoit, J.P. (2008) Brain targeting using novel lipid nanovectors. J. Control Release, 126(1), 44-49. (Pubitemid 351175685)
50. Cerletti, A., Drewe, J., Fricker, G., Eberle, A.N., Huwyler, J. (2000) Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. J. Drug Target, 8(6), 435-446. (Pubitemid 32366711)
51. Ji, B., Maeda, J., Higuchi, M., Inoue, K., Akita, H., Harashima, H., Suhara, T. (2006) Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci., 78(8), 851-855. (Pubitemid 43082309)
52. Boado, R.J., Zhang, Y., Zhang, Y., Wang, Y., Pardridge, W.M. (2008) GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnol. Bioeng., 100(2), 387-396. (Pubitemid 351758180)
53. Triguero, D., Buciak, J.B., Yang, J., Pardridge, W.M. (1989) Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein. Proc. Natl. Acad. Sci. USA, 86(12), 4761-4765. (Pubitemid 19164629)
54. Lu, W., Tan, Y.Z., Hu, K.L., Jiang, X.G. (2005) Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier. Int. J. Pharm., 295(1-2), 247-260. (Pubitemid 40558807)
55. Thöle, M., Nobmanna, S., Huwyler, J., Bartmann, A., Fricker, G. (2002) Uptake of cationzied albumin coupled liposomes by cultured porcine brain microvessel endothelial cells and intact brain capillaries. J. Drug Target, 10(4), 337-344. (Pubitemid 34746315)
56. Lu, W., Wan, J., She, Z., Jiang, X. (2007) Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J. Control Release, 118(1), 38-53. (Pubitemid 46283096)
57. Riedl, P., Reimann, J., Schirmbeck, R. (2004) Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines. J. Mol. Med., 82(2), 144-152. (Pubitemid 38299713)
58. Tang, Y., Han, T., Everts, M., Zhu, Z.B., Gillespie, G.Y., Curiel, D.T., Wu, H. (2007) Directing adenovirus across the blood-brain barrier via melanotransferrin (P97) transcytosis pathway in an in vitro model. Gene Ther., 14(6), 523-532. (Pubitemid 46390925)
59. Demeule, M., Poirier, J., Jodoin, J., Bertrand, Y., Desrosiers, R.R., Dagenais, C., Nguyen, T., Lanthier, J., Gabathuler, R., Kennard, M., Jefferies, W.A., Karkan, D., Tsai, S., Fenart, L., Cecchelli, R., Béliveau, R. (2002) High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J. Neurochem., 83(4), 924-933. (Pubitemid 35316043)
60. Pan, W., Kastin, A.J., Zankel, T.C., van Kerkhof, P., Terasaki, T., Bu, G. (2004) Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J. Cell Sci., 117(Pt 21), 5071-5078. (Pubitemid 39517522)
61. Wilson, B., Samanta, M.K., Santhi, K., Kumar, K.P., Paramakrishnan, N., Suresh, B. (2008) Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res., 1200, 159-168.
62. Ambruosi, A., Khalansky, A.S., Yamamoto, H., Gelperina, S.E., Begley, D.J., Kreuter, J. (2006) Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastomabearing rats. J. Drug Target, 14(2), 97-105.
63. Michaelis, K., Hoffmann, M.M., Dreis, S., Herbert, E., Alyautdin, R.N., Michaelis, M., Kreuter, J., Langer, K. (2006) Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharmacol. Exp. Ther., 317(3), 1246-1253. (Pubitemid 43764130)
64. Karkan, D., Pfeifer, C., Vitalis, T.Z., Arthur, G.; Ujiie, M., Chen, Q., Tsai, S., Koliatis, G., Gabathuler, R., Jefferies, W.A. (2008) A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS ONE, 253(6), e2469.
65. Kreuter, J., Ramge, P., Petrov, V., Hamm, S., Gelperina, S.E., Engelhardt, B., Alyautdin, R., von Briesen, H., Begley, D.J. (2003) Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res., 20(3), 409-416. (Pubitemid 36288370)
66. Gao, K., Jiang, X. (2006) Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int. J. Pharm., 310(1-2), 213-219. (Pubitemid 43287986)
67. Zhou, S.F. (2008) Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica, 38(7-8), 802-832.
68. Juliano, R.L., Ling, V. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 455, 152-162.
69. Goldstein, L.J., Galski, H., Fojo, A., Willingham, M., Lai, S., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G.M., Lieber, M., Cossman, J., Gottesman, M.M., Pastan, I. (1989) J. Natl. Cancer Inst., 81, 116-124.
70. Pinedo, H.M. Giaccone, G. (1995) P-glycoprotein - a marker of cancer-cell behavior. N. Engl. J. Med., 333, 1417-1419.
71. Scotlandi, K., Manara, M.R., Serra, M., Benini, S., Maurici, D., Caputo, A., De Giovanni, C., Lollini, P.L., Nanni, P., Picci, P., Campanacci, M., Baldini, N. (1999) The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene, 18, 739-746. (Pubitemid 29080331)
72. Fojo, A.T., Ueda, K., Slamon, D.J., Poplack, D.G., Gottesman, M.M., Pastan, I. (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA, 84, 265-269. (Pubitemid 17013615)
73. Gottesman, M.M., Pastan, I. (1988) The multidrug transporter, a double-edged sword. J. Biol. Chem., 263, 12163-12166.
74. Hennessy, M., Spiers, J.P. (2007) A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol. Res., 55, 1-15. (Pubitemid 46108588)
75. Jonker, J.W., Wagenaar, E., van Deemter, L., Gottschlich, R., Bender, H.M., Dasenbrock, J., Schinkel, A.H. (1999) Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. Br. J. Pharmacol., 127, 43-50. (Pubitemid 29213230)
76. Batrakova, E.V., Li, S., Vinogradov, S.V., Alakhov, V.Y., Miller, D.W., Kabanov, A.V. (2001) Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther., 299(2), 483-493. (Pubitemid 32979659)
77. Wong, H.L., Bendayan, R., Rauth, A.M., Wu, X.Y. (2006) Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J. Control Release, 116(3), 275-284. (Pubitemid 44827405)
78. Bihorel, S., Camenisch, G., Lemaire, M., Scherrmann, J.M. (2007) Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm. Res., 24(9), 1720-1728. (Pubitemid 47206611)
79. Weber, C.C., Reising, K., Müller, W.E., Schubert-Zsilavecz, M., Abdel-Tawab, M. (2006) Modulation of Pgp function by boswellic acids. Planta Med., 72(6), 507-513. (Pubitemid 43844677)
80. Green, M., Loewenstein, P. M. (1988) Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell, 55, 1179-1188. (Pubitemid 19020070)
81. Frankel, A.D., Pabo, C.O. (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell, 55, 1189-1193. (Pubitemid 19020071)
82. Soane, L., Fiskum, G. (2005) TAT-mediated endocytotic delivery of the loop deletion Bcl-2 protein protects neurons against cell death. J. Neurochem., 95(1), 230-243. (Pubitemid 41384441)
83. Nori, A., Jensen, K.D., Tijerina, M., Kopeckova, P., Kopecek, J. (2003) Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells. Bioconj. Chem., 14, 44-50. (Pubitemid 36169015)
84. Zhao, M., Kircher, M.F., Josephson, L., Weissleder, R. (2002) Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconj. Chem., 13, 840-844. (Pubitemid 34801127)
85. Lewin, M., Carlesso, N., Tung, C.H., Tang, X.W., Cory, D., Scadden, D.T., Weissleder, R. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol., 18, 410-414.
86. Liu, L., Venkatraman, S.S., Yang, Y.Y., Guo, K., Lu, J., He, B., Moochhala, S., Kan, L. (2008) Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier. Biopolymers, 90(5), 617-623.
87. Schwarze, S.R., Ho, A., Vocero-Akbani, A., Dowdy, S.F. (1999) In vivo protein transduction:delivery of a biologically active protein into the mouse. Science, 285, 1569-1572. (Pubitemid 29420581)
88. Rousselle, C., Smirnova, M., Clair, P., Lefauconnier, J.M., Chavanieu, A., Calas, B., Scherrmann, J.M., Temsamani, J. (2001) Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. J. Pharmacol. Exp. Ther., 296(1), 124-131. (Pubitemid 32015070)
89. Mazel, M., Clair, P., Rousselle, C., Vidal, P., Scherrmann, J.M., Mathieu, D., Temsamani, J. (2001) Doxorubicin-peptide conjugates overcome multidrug resistance. Anticancer Drugs, 12(2), 107-116. (Pubitemid 32207359)
90. Santra, S., Yang, H., Stanley, J.T., Holloway, P.H., Moudgil, B.M., Walter, G., Mericle, R.A. (2005) Rapid and effective labeling of brain tissue using TAT-conjugated CdS:Mn/ZnS quantum dots. Chem. Commun. (Camb), 25, 3144-3146. (Pubitemid 41002376)
91. Santra, S., Yang, H., Dutta, D., Stanley, J.T., Holloway, P.H., Tan, W., Moudgil, B.M., Mericle, R.A. (2004) TAT conjugated, FITC doped silica nanoparticles for bioimaging applications. Chem. Commun. (Camb), 24, 2810-2811. (Pubitemid 40064799)
92. Casacchia, M., Meco, G., Pirro, R., Di Cesare, E., Allegro, A., Cusimano, G., Marola, W. (1982) Phospholipid liposomes in depression: a double-blind study versus placebo. Int. Pharmacopsychiat., 17, 274.
93. Dass, C.R. (2008) Drug delivery in cancer using liposomes. Methods Mol. Biol., 437, 177-182.
94. Schwendener, R.A. (2007) Liposomes in biology and medicine. Adv. Exp. Med. Biol., 620, 117-128.
95. Béduneau, A., Saulnier, P., Benoit, J.P. (2007) Active targeting of brain tumors using nanocarriers. Biomaterials, 28(33), 4947-4967. (Pubitemid 47362345)
96. Medina, O.P., Zhu, Y., Kairemo, K. (2004) Targeted liposomal drug delivery in cancer. Curr. Pharm. Des., 10(24), 2981-2989. (Pubitemid 39214006)
97. Shao, K., Hou, Q., Duan, W., Go, M.L., Wong, K.P., Li, Q.T. (2006) Intracellular drug delivery by sulfatide-mediated liposomes to gliomas. J. Control Release, 115(2), 150-157. (Pubitemid 44559706)
98. Pastorino, F., Mumbengegwi, D.R., Ribatti, D., Ponzoni, M., Allen, T.M. (2008) Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. J. Control Release, 126(1), 85-94.
99. Immordino, M.L., Brusa, P., Arpicco, S., Stella, B., Dosio, F., Cattel, L. (2003) Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. Control Release, 91(3), 417-429. (Pubitemid 36980659)
100. Momekova, D., Rangelov, S., Yanev, S., Nikolova, E., Konstantinov, S., Romberg, B., Storm, G., Lambov, N. (2007) Long-circulating, pH-sensitive liposomes sterically stabilized by copolymers bearing short blocks of lipid-mimetic units. Eur. J. Pharm. Sci., 32(4-5), 308-317. (Pubitemid 350051894)
101. Chen, L.C., Chang, C.H., Yu, C.Y., Chang, Y.J., Hsu, W.C., Ho, C.L., Yeh, C.H., Luo, T.Y., Lee, T.W., Ting, G. (2007) Biodistribution, pharmacokinetics and imaging of (188)Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl. Med. Biol., 34(4), 415-423.
102. Cattel, L., Ceruti, M., Dosio, F. (2004) From conventional to stealth liposomes: a new Frontier in cancer chemotherapy. J. Chemother., 16(Suppl 4), 94-97. (Pubitemid 40065293)
103. Torchilin, V.P. (1994) Immunoliposomes and PEGylated immunoliposomes: possible use for targeted delivery of imaging agents. Immunomethods, 4(3), 244-258.
104. Barenholz, Y. (2001) Liposome application: problems and prospects. Curr. Opin. Colloid Interface Sci., 6, 66-77.
105. Sonavane, G., Tomoda, K., Makino, K. (2008) Biodistribution of colloidal gold nanoparticles after intravenous administration: Effect of particle size. Colloids Surf. B Biointerfaces, 66(2), 274-280.
106. De Jong, W.H., Borm, P.J. (2008) Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomed., 3(2), 133-149. (Pubitemid 352042401)
107. Tosi, G., Costantino, L., Ruozi, B., Forni, F., Vandelli, M.A. (2008) Polymeric nanoparticles for the drug delivery to the central nervous system. Exp. Opin. Drug Deliv., 5(2), 155-174. (Pubitemid 351308309)
108. Suri, S.S., Fenniri, H., Singh, B. (2007) Nanotechnology-based drug delivery systems. J. Occup. Med. Toxicol., 2, 16.
109. Bala, I., Hariharan, S., Kumar, M.N. (2004) PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier Syst., 21(5), 387-422. (Pubitemid 41647578)
110. Arayne, M.S., Sultana, N., Noor-Us-Sabah. (2007) Fabrication of solid nanoparticles for drug delivery. Pak. J. Pharm. Sci., 20(3), 251-259.
111. Chauvierre, C., Vauthier, C., Labarre, D., Couvreur, P., Marden, M.C., Leclerc, L. (2004) A new generation of polymer nanoparticles for drug delivery. Cell Mol. Biol. (Noisy-le-grand), 50(3), 233-239.
112. Chow, P. Y., Gan L.M. (2004) Microemulsion processing of silica-polymer nanocomposites. J. Nanosci. Nanotechnol., 4(1-2), 197-202.
113. Puglisi, G., Giammona, M.F., Ventura, C.A. (1995) Influence of the preparation conditions on poly (ethylcyanoacrylate) nanocapsule formation. Int. J. Pharm., 125, 283-287.
114. Quintanar-Guerrero D., Allémann E., Doelker E., Fessi H. (1998) Preparation and characterization of nanocapsules from preformed polymers by a new process based on emulsification-diffusion technique. Pharm. Res., 15(7), 1056-1062. (Pubitemid 28356923)
115. Rao, K.S., Reddy, M.K., Horning, J.L., Labhasetwar, V. (2008) TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials, 29(33), 4429-4438.
116. Park, J.H., Lee, S.K., Kim, J.H., Park, K.S., Kim, K.M., Kwon, I.K. (2008) Polymeric nanomedicine for cancer therapy. Prog. Polymer Sci., 33, 113-137.
117. Narang, A.S., Delmarre, D., Gao, D. (2007) Stable drug encapsulation in micelles and microemulsions. Int. J. Pharm., 345, 9-25. (Pubitemid 350103649)
118. La, S.B., Okano, T., Kataoka, K. (1996) Preparation and characterization of the micelle-forming polymeric drug indomethacin-incorporated poly(ethylene oxide)-poly(beta-benzyl L-aspartate) block copolymer micelles. J. Pharm. Sci., 85, 85-90. (Pubitemid 26029075)
119. Adams, M.L., Lavasanifar, A., Kwon, G.S. (2003) Amphiphilic block copolymers for drug delivery. J. Pharm. Sci., 92, 1343-1355. (Pubitemid 36792748)
120. Allen, C., Maysinger, D., Eisenberg, A. (1999) Nano-engineering block copolymer aggregates for drug delivery. Colloids Surf. B Biointerfaces, 16, 3-27. (Pubitemid 29486794)
121. Batrakova, E.V., Li, S., Vinogradov, S.V., Alakhov, V.Y., Miller, D.W., Kabanov, A.V. (2001) Mechanism of pluronic effect on Pglycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther., 299, 483-493. (Pubitemid 32979659)
122. Batrakova, E.V., Miller, D.W., Li, S., Alakhov, V.Y., Kabanov, A.V., Elmquist, W.F., Pluronic (2001) P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J. Pharmacol. Exp. Ther., 296, 551-557.
123. Batrakova, E.V., Kabanov, A.V. (2008) Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Control Release, 130, 98-106.
124. Kabanov, A.V., Batrakova, E.V., Melik-Nubarov, N.S., Fedoseev, N.A., Dorodnich, T.Y., Alakhov, V.Y., Chekhonin, V.P., Nazarova, I.R., Kabanov, V.A. (1992) New classes of drug carries: micelles of poly(oxyethylene)- poly(oxypropylene) block copolymers as microcontainers for drug targeting form blood in brain. J. Control Release, 22, 141-158.
125. Gaucher, G., Dufresne, M.H., Sant, V.P., Kang, N., Maysinger, D., Leroux, J.C. (2005) Block copolymer micelles: preparation, characterization and application in drug delivery. J. Control Release, 109, 169-188. (Pubitemid 41742123)
126. Torchilin, V.P. (2004) Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol. Life Sci., 61, 2549-2559.
127. Vakil, R., Kwon, G.S. (2005) PEG-phospholipid micelles for the delivery of amphotericin B. J. Control Release, 101, 386-389.
128. Torchilin, V.P., Trubetskoy, V.S., Whiteman, K.R., Caliceti, P., Ferruti, P., Veronese, FM. (1995) New synthetic amphiphilic polymers for steric protection of liposomes in vivo. J. Pharm. Sci., 84, 1049-1053.
129. Yamamoto, Y., Nagasaki, Y., Kato, Y., Sugiyama, Y., Kataoka, K. (2001) Long-circulating poly(ethylene glycol)-poly(-lactide) block copolymer micelles with modulated surface charge. J. Control Release, 77, 27-38. (Pubitemid 33022613)
130. Nakayama, M., Okano, T., Miyazaki, T., Kohori, F., Sakai, K., Yokoyama, M. (2006) Molecular design of biodegradable polymeric micelles for temperature-responsive drug release. J. Control Release, 28, 46-56.
131. Nakanishi, T., Fukushima. S., Okamoto, K., Suzuki, M., Matsumura, Y., Yokoyama, M., Okano, T, Sakurai, Y, Kataoka, K. (2001) Development of the polymer micelle carrier system for doxorubicin. J. Control Release, 74, 295-302. (Pubitemid 32727635)
132. Garrec, L., Gori, D., Karkan, S., Luo, D., Lessard, L., Smith, D.G., Ranger, M., Yessine, M.-A., Leroux, J.-C. (2005) Preparation, characterization, cytotoxicity and biodistribution of docetaxel-loaded polymeric micelle formulations. J. Drug Deliv. Sci. Technol., 15, 115-120. (Pubitemid 40477974)
133. Chunder, A., Sarkar, S., Yu, Y., Zhai, L. (2007) Fabrication of ultrathin polyelectrolyte fibers and their controlled release properties. Colloids Surf. B Biointerfaces, 58, 172-179. (Pubitemid 46921454)
134. Glinel, K., Déjugnat, C., Prevot, M., Schöler, B., Schönhoff, M. V., Klitzing, R. (2007) Responsive polyelectrolyte multilayers. Colloids Surf. A: Physicochem. Eng. Asp., 303, 3-13.
135. Zhu, Y., Shi, J. (2007) A mesoporous core-shell structure for pH-controlled storage and release of water-soluble drug. Microporous Mesoporous Mater., 103, 243-249. (Pubitemid 46810341)
136. Costantino, L., Gandolfi, F., Tosi, G., Rivasi, F., Vandelli, M.A., Forni, F. (2005) Peptide-derivatized biodegradable nanoparticles able to cross the blood brain barrier. J. Control Release, 108, 84-96. (Pubitemid 41476677)
137. Liu, L., Guo, K., Lu. J., Venkatraman, S.S., Luo, D., Ng, K.C., Ling, E.A., Moochhala, S., Yang, Y.Y. (2008) Biologically active core shell nanoparticles self-assembled from cholesterol terminated PEG-TAT for drug delivery across the BBB. Biomaterials, 29, 1509-1517.
138. Almeida, A.J., Souto, E. (2007) Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev., 59(6), 478-490. (Pubitemid 47260710)
139. Blasi, P., Giovagnoli, S., Schoubben, A., Ricci, M., Rossi, C. (2007) Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev., 59(6), 454-477. (Pubitemid 47259226)
140. Diederichs, J.E., Muller, R.H. (1994) Liposomes in cosmetics and pharmaceutical products. Pharm. Ind., 56, 267-275.
141. Freitas, C., Müller, R.H. (1998) Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticles (SLN) dispersions. Int. J. Pharm., 168, 221-229. (Pubitemid 28349963)
142. Vinogradov, S.V., Bronich, T.K., Kabanov, A.V. (2002) Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv. Drug Deliv. Rev., 54, 135-147.
143. Vinogradov, S.V., Batrakova, E.V., Kabanov, A.V. (1999) Poly (ethyleneglycol)-polyethyleneimine NanoGel particles: novel drug delivery systems for antisense oligonucleotides. Colloids Surf. B: Biointerfaces, 16, 291-304.
144. Gilmore, J.L., Yi, X., Quan, L., Kabanov, A.V. (2008) Novel nanomaterials for clinical neuroscience. J. Neuroimmune Pharmacol., 3, 83-94.
145. Hahn, U., Gorka, M., Vogtle, F., Vicinelli, V., Ceroni, P., Maestri, M., Balzani, V. (2002) Light-harvesting dendrimers: efficient intra- and intermolecular energy-transfer processes in a species containing 65 chromophoric groups of four different types. Angew. Chem. Int. Ed. Engl., 41, 3595-3598, 3514.
146. Yang, H., Kao, W.J. (2006) Dendrimers for pharmaceutical and biomedical applications. J. Biomater. Sci. Polym. Ed., 17, 3-19.
147. Wu, G., Barth, R.F., Yang, W., Kawabata, S., Zhang, L., Green-Church, K. (2006) Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther., 5, 52-59.
148. Dhanikula, R.S., Argaw, A., Bouchard, J.F., Hildgen, P. (2008) Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol. Pharm., 5, 105-116. (Pubitemid 351300040)
149. Wang, J., Yong, W.H., Sun, Y., Vernier, P.T., Koeffler, H.P., Gundersen, M.A., Marcu. L. (2007) Receptor-Targeted quantum dots: fluorescent probes for brain tumor diagnosis. J. Biomed. Opt., 12, 044021.
150. Choi, A.O., Cho, S.J., Desbarats, J., Lovric, J., Maysinger, D. (2007) Quantum dot-induced cell death involves Fas upregulation and lipid peroxidation in human neuroblastoma cells. J. Nanobiotechnol., 5, 1.
151. Hardman, R. (2006) A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ. Health Perspect., 114, 165-172.
152. Tang, M., Xing, T., Zeng, J., Wang, H., Li, C., Yin, S., Yan, D., Deng, H., Liu, J., Wang, M., Chen, J., Ruan, D.Y. (2008) Unmodified CdSe quantum dots induce elevation of cytoplasmic calcium levels and impairment of functional properties of sodium channels in rat primary cultured hippocampal neurons. Environ. Health Perspect., 116, 915-922. (Pubitemid 351943899)
153. Strijkers, G.J., Mulder, W.J., van Tilborg, G.A., Nicolay, K. (2007) MRI contrast agents: current status and future perspectives. Anticancer Agents Med. Chem., 7, 291-305. (Pubitemid 46813466)
154. Cheng, F.Y., Wang, S.P., Su, C.H., Tsai, T.L., Wu, P.C., Shieh, D.B., Chen, J.H., Hsieh, P.C., Yeh, C.S. (2008) Stabilizer-free poly(lactide-co- glycolide) nanoparticles for multimodal biomedical probes. Biomaterials, 29, 2104-2112.
155. Babic, M., Horák, D., Trchová, M., Jendelová, P.,
156. Meincke, M., Schlorf, T., Kossel, E., Jansen, O., Glueer, C.C., Mentlein, R. (2008) Iron oxide-loaded liposomes for MR imaging. Front Biosci., 13, 4002-4008.
157. Meng, X.X., Wan, J.Q., Jing, M., Zhao, S.G., Cai, W., Liu, E.Z. (2007) Specific targeting of gliomas with multifunctional superparamagnetic iron oxide nanoparticle optical and magnetic resonance imaging contrast agents. Acta Pharmacol. Sin., 28, 2019-2026. (Pubitemid 350198333)
158. Sun, C., Veiseh, O., Gunn, J., Fang, C., Hansen, S., Lee, D., Sze, R, Ellenbogen, R.G., Olson, J., Zhang, M. (2008) In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small, 4, 372-379.